SECOND OPINIONS FOR
UNRESECTABLE CANCER
'Unresectable' is not a diagnosis — it is a judgement call. And judgement calls made by surgeons who perform 50 procedures per year are different from those made by surgeons who perform 500.
analyticsAt a Glance
- check_circle20–40% of patients told their cancer is unresectable are offered surgery at high-volume specialist centres
- check_circleResectability assessment is volume-dependent — a surgeon performing 500 hepatectomies per year draws different boundaries than one performing 50
- check_circleAdvanced surgical techniques (ALPPS, portal vein embolisation, robotic surgery) have expanded the definition of resectable in the past decade
- check_circleCancerFax coordinates surgical resectability second opinions at leading specialist centres in China, India, and internationally
Why 'Unresectable' Is Not a Fixed Diagnosis
Resectability is not an objective measurement — it is a clinical judgement that depends on the surgeon's experience and technique repertoire, the technology available at the institution (robotics, intraoperative ultrasound, real-time navigation), the patient's fitness and reserve organ function, and whether downstaging with systemic therapy or locoregional treatment has been attempted. All of these variables change when you change the surgeon or the centre.
“The margin between resectable and unresectable is not a line in the anatomy — it is a line in the surgeon's experience. Move the surgeon, and the line moves.”
Volume Is the Primary Variable
A surgeon performing 500 hepatectomies per year has encountered the same anatomical challenge dozens of times, developed techniques to address it safely, and has outcome data to support a more aggressive approach. A surgeon performing 50 per year draws the boundary of 'safe' resection differently — not because the anatomy is different, but because their experience with risk management is.
Surgical Techniques Have Advanced
ALPPS (associating liver partition and portal vein ligation for staged hepatectomy), portal vein embolisation for future liver remnant hypertrophy, anatomical segmentectomy guided by 3D reconstruction, and robotic-assisted precision resection have all expanded what is surgically achievable in the last decade — techniques not available at all centres.
How Often Does the Unresectable Verdict Change?
Published data across multiple cancer types and specialist centres quantifies the frequency with which high-volume surgical review reverses an unresectable verdict.
- 20–40%Overall rate of resectability reversal at high-volume specialist centresAcross liver, pancreatic, lung, and colorectal cancer series, published data consistently shows 20–40% of patients referred as unresectable are offered surgery after review by subspecialist high-volume surgical teams.
- 30%+HCC patients told unresectable who are offered surgery at Zhongshan HospitalCancerFax case experience and Zhongshan published series: approximately 30% of hepatocellular carcinoma patients referred as 'unresectable' are offered hepatic resection after imaging review by Zhongshan's hepatobiliary team.
- 15–25%Pancreatic cancer borderline-resectable cases upgraded to resectable at specialist centresBorderline-resectable pancreatic cancer requires multidisciplinary assessment by a team performing high-volume pancreatectomies — specialist review upgrades resectability status in 15–25% of referred borderline cases.
Resectability Second Opinion by Cancer Type
Different cancer types have different rates of resectability verdict change — driven by the volume-dependency of the surgical assessment and the pace of technical advancement in each area.
| Cancer Type | Rate of Verdict Change at Specialist Review | Key Drivers of Change | Best Second Opinion Centre Type |
|---|---|---|---|
| Hepatocellular carcinoma (HCC) | 25–35% of referred cases | Surgical volume (4,000+ hepatectomies/year vs 200); ALPPS; portal vein embolisation for future liver remnant | Zhongshan Hospital Shanghai; SYSUCC Guangzhou — world's highest HCC surgical volumes |
| Colorectal liver metastases | 20–30% of referred cases | Advances in staged hepatectomy; simultaneous resection of primary + liver in expert hands; percutaneous ablation for residual lesions | Hepatobiliary surgery units at Tata Memorial, AIIMS, or Chinese academic centres with >500 hepatectomies/year |
| Pancreatic cancer (borderline-resectable) | 15–25% of borderline-resectable cases | Vascular reconstruction capability; neoadjuvant downstaging before re-staging; IORT availability | Dedicated pancreatic surgery centres — Johns Hopkins, MD Anderson, Tata Memorial, or German pancreatic cancer centres |
| Lung cancer (locally advanced, N2 disease) | 20–30% of referred Stage IIIA/IIIB cases | Advances in sleeve resection; minimally invasive thoracoscopic techniques; neoadjuvant immunotherapy enabling downstaging before surgery | High-volume thoracic surgery centres — CAMS Beijing, FUSCC Shanghai, Apollo, or European thoracic centres |
| Rectal cancer (T4b, locally advanced) | 15–25% of referred cases | Pelvic exenteration capability at tertiary centres; IORT; preoperative LCRRT enabling downstaging | Tata Memorial Centre; Apollo Hospitals; German rectal cancer reference centres |
| Cholangiocarcinoma (hilar, intrahepatic) | 20–30% of referred cases | Hepatobiliary surgical expertise; portal vein embolisation; anatomical 3D planning from CT angiography | Zhongshan Hospital; FUSCC; PKUPH — hepatobiliary oncology specialist centres |
How to Seek a Resectability Second Opinion Through CancerFax
A resectability second opinion is primarily an imaging review — high-quality cross-sectional imaging with appropriate protocols is the critical input. The process is structured to deliver a preliminary answer within 7–14 days without requiring travel.
- 1
Submit High-Quality Imaging (DICOM)
For a resectability review, the quality of imaging is everything. Provide: triple-phase CT (arterial, portal venous, delayed phases) and/or MRI with liver-specific contrast where relevant; CT chest for pulmonary metastasis assessment; recent PET-CT where available. All as full DICOM files — not printed films. Images should be from within the last 4–6 weeks.
- 2
Include Operative Reports from Prior Surgery
If prior surgery was attempted and abandoned for unresectability, the operative report is essential — it documents exactly what anatomical challenge was encountered. This allows the second opinion surgeon to understand not just the imaging but the operative findings.
- 3
Provide 3D Reconstruction Imaging If Available
3D volume rendering and CT angiography with vascular anatomy mapping significantly assist the reviewing surgeon's assessment. Many specialist centres perform their own 3D reconstruction from submitted DICOM files — CancerFax requests this from the receiving centre where needed.
- 4
Remote Surgical Review — Resectability Decision Within 7–14 Days
CancerFax submits imaging to the relevant specialist surgical team with a focused question: 'Is resection feasible at your centre, and under what conditions?' The surgical team reviews imaging and provides a written preliminary resectability assessment.
- 5
In-Person Pre-Surgical Assessment if Surgery Is Offered
If the remote review identifies resectability, CancerFax coordinates an in-person pre-operative assessment — including any additional investigations the surgical team requires before finalising the operative plan. This is the point at which travel is arranged.
Downstaging First, Then Reassessment: A Pathway to Resectability
For patients who remain truly unresectable at specialist review, systemic or locoregional downstaging therapy followed by re-assessment is a recognised pathway to converting an unresectable tumour to a resectable one — and should be discussed at every second opinion.
Conversion Therapy Approaches
- HAIC + targeted therapy for HCCHAIC-FOLFOX combined with lenvatinib or anti-PD-1 achieves conversion resection in 30–40% of initially unresectable HCC — the strongest conversion strategy for this tumour type, primarily available in China.
- Neoadjuvant FOLFIRINOX or gemcitabine + nab-paclitaxel for pancreatic cancerNeoadjuvant chemotherapy followed by re-staging CT converts borderline-resectable to resectable in 20–30% of pancreatic cancer patients — a well-established pathway requiring multidisciplinary centre assessment.
- Neoadjuvant immunotherapy + chemotherapy for lung cancerNeoadjuvant atezolizumab or nivolumab combined with platinum-based chemotherapy achieves sufficient downstaging for resection in selected Stage IIIA NSCLC patients previously deemed unresectable.
Conversion Rates Published in Evidence
- HCC conversion to resection after HAIC: 30–40%Zhongshan Hospital and SYSUCC published series demonstrate 30–40% conversion resection rates after HAIC-based downstaging — the most powerful conversion data in any solid tumour type.
- Pancreatic cancer conversion after neoadjuvant: 20–30%Multiple prospective series show 20–30% conversion to R0 resection after neoadjuvant FOLFIRINOX in borderline-resectable pancreatic cancer — with 5-year survival approaching resected early-stage disease in responders.
- Colorectal liver metastases conversion after FOLFOX/FOLFIRI ± bevacizumab: 10–20%Response to systemic chemotherapy enables 10–20% of initially unresectable colorectal liver metastases to become resectable — mandating reassessment CT every 2–3 cycles in all patients.
Frequently Asked Questions
Common questions from patients who have been told their cancer is unresectable.
About Unresectable Cancer Second Opinions
My oncologist and the surgeon both say it's inoperable — should I still get a second opinion?
Yes — and this is precisely the situation where a second opinion has the highest clinical yield. When both an oncologist and a surgeon at the same institution reach the same conclusion, they may be applying the same institutional threshold — which may be more conservative than a specialist centre with five times the surgical volume. The question is not whether your local team is wrong, but whether a surgeon with deeper subspeciality volume would draw the line differently. CancerFax coordinates remote imaging review by such surgeons within 7–14 days.
What imaging should I provide for a resectability review?
For a meaningful resectability assessment: (1) triple-phase CT from within the last 4–6 weeks as DICOM files; (2) MRI abdomen with liver-specific contrast (gadoxetate) where liver involvement is the issue; (3) CT chest for pulmonary staging; (4) PET-CT where available for distant staging. Quality and recency of imaging are the most important variables — old or low-quality images cannot support a meaningful resectability assessment.
If I am told I am resectable at a Chinese centre, do I have to have surgery there?
No — but the practical implications matter. If the Chinese centre's assessment is that surgery is feasible there but not at your local centre, the surgery will likely need to be performed at the Chinese centre where the volume and technique exist. CancerFax manages the full process: remote resectability assessment, in-person pre-operative assessment if surgery is confirmed, surgical procedure, and post-operative follow-up coordination with your home oncologist.
What is ALPPS and why does it change resectability?
ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy) is a two-stage surgical procedure that rapidly hypertrophies the future liver remnant in 7–14 days — enabling resection of tumours that would leave an inadequate liver remnant with a single-stage approach. It is performed only at high-volume hepatobiliary centres and has expanded the definition of 'resectable' for patients with bilobar liver tumours or limited future liver remnant. CancerFax identifies centres with ALPPS capability during resectability review.
More from the Cancer Second Opinion Resource Library
Explore related second opinion guides — from liver cancer specifics to second opinion costs and process.
- ↑ Cancer Second Opinion — Complete Guide
- Second Opinions for Liver Cancer and HCC: Why China's Centres Change Management
- Cancer Second Opinion Costs: India vs China vs USA
- How CancerFax Facilitates Second Opinions: From First Contact to Delivery
- What Is a Cancer Second Opinion and Why Should Every Patient Consider One?
- Cancer Second Opinions in China: Zhongshan, Fudan, and Sun Yat-sen
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Request a Resectability Second Opinion Through CancerFax
CancerFax coordinates surgical second opinions for patients told their cancer is unresectable — submitting imaging to high-volume subspecialist surgical teams in China, India, and internationally for independent resectability assessment. Remote imaging reviews are delivered within 7–14 days.
This content is for informational purposes only and does not constitute medical advice. Resectability assessment must be made by a qualified surgical oncologist reviewing current imaging.